FDA approves Novartis osteoarthritis treatment

10/23/2007 | Forbes · Reuters

Novartis AG's topical treatment for osteoarthritis, called Voltaren Gel, was awarded FDA approval, the company announced Monday. Clinical trials showed that the nonsteroidal anti-inflammatory drug can reduce pain in both the knees and joints of the hands by 51% with minimal side effects.

View Full Article in:

Forbes · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC